Gary L. Rosner
Researcher Next ID · RN-022997
Researcher · Mathematics
United States Food and Drug Administration
Silver Spring, Thailand
- Works count
- 335
- Citation count
- 16,954
- H-index
- 66
- i10-index
- 183
Research interests
Publications
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2020-001282
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Blood Advances · 2020 · 10.1182/bloodadvances.2020001729
Haploidentical BMT for severe aplastic anemia with intensive GVHD prophylaxis including posttransplant cyclophosphamide
Blood Advances · 2020 · 10.1182/bloodadvances.2020001729
Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
Journal for ImmunoTherapy of Cancer · 2020 · 10.1136/jitc-2020-001282
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
New England Journal of Medicine · 2018 · https://doi.org/10.1056/nejmoa1716078
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Haematologica · 2016 · 10.3324/haematol.2016.144139
Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide
Haematologica · 2016 · 10.3324/haematol.2016.144139
Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide
Blood · 2015 · 10.1182/blood-2015-01-623991
Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults
Journal of Clinical Oncology · 2015 · 10.1200/jco.2014.60.4777
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Blood · 2014 · 10.1182/blood-2014-07-587477
Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS
Blood · 2014 · 10.1182/blood-2014-07-587477
Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2012 · 10.1200/jco.2011.39.9436
DPpackage: Bayesian Semi- and Nonparametric Modeling inR
Journal of Statistical Software · 2011 · 10.18637/jss.v040.i05
DPpackage: Bayesian Semi- and Nonparametric Modeling inR
Journal of Statistical Software · 2011 · 10.18637/jss.v040.i05
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition
Genome Research · 2011 · 10.1101/gr.129668.111
Bayesian Nonparametric Nonproportional Hazards Survival Modeling
Biometrics · 2009 · 10.1111/j.1541-0420.2008.01166.x
Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics
Journal of Clinical Oncology · 2009 · 10.1200/jco.2008.20.6300
Bayesian Nonparametric Nonproportional Hazards Survival Modeling
Biometrics · 2009 · 10.1111/j.1541-0420.2008.01166.x
Ancestry and pharmacogenetics of antileukemic drug toxicity
Blood · 2007 · https://doi.org/10.1182/blood-2006-10-054528
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
Blood · 2007 · 10.1182/blood-2007-06-098061
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology · 2006 · https://doi.org/10.1200/jco.2005.03.6723
Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia
Blood · 2006 · 10.1182/blood-2006-03-009142
MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer
JNCI Journal of the National Cancer Institute · 2005 · 10.1093/jnci/dji275
An ANOVA Model for Dependent Random Measures
Journal of the American Statistical Association · 2004 · 10.1198/016214504000000205
Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia
Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.11.020
A Method for Combining Inference Across Related Nonparametric Bayesian Models
Journal of the Royal Statistical Society Series B (Statistical Methodology) · 2004 · 10.1111/j.1467-9868.2004.05564.x
Pharmacogenetic Risk Factors for Osteonecrosis of the Hip Among Children With Leukemia
Journal of Clinical Oncology · 2004 · 10.1200/jco.2004.11.020
A Method for Combining Inference Across Related Nonparametric Bayesian Models
Journal of the Royal Statistical Society Series B (Statistical Methodology) · 2004 · 10.1111/j.1467-9868.2004.05564.x
Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.11.126
Randomized Discontinuation Design: Application to Cytostatic Antineoplastic Agents
Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.11.126
Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565
Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.14.2780
Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565
Journal of Clinical Oncology · 2000 · 10.1200/jco.2000.18.14.2780
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Journal of Clinical Oncology · 1996 · 10.1200/jco.1996.14.11.3000
Relationship between toxicity and obesity in women receiving adjuvant chemotherapy for breast cancer: results from cancer and leukemia group B study 8541.
Journal of Clinical Oncology · 1996 · 10.1200/jco.1996.14.11.3000
Prophylactic Intravenous Amphotericin B in Neutropenic Autologous Bone Marrow Transplant Recipients
The Journal of Infectious Diseases · 1992 · 10.1093/infdis/165.5.891
Prophylactic Intravenous Amphotericin B in Neutropenic Autologous Bone Marrow Transplant Recipients
The Journal of Infectious Diseases · 1992 · 10.1093/infdis/165.5.891
Exact Confidence Intervals Following a Group Sequential Test
Biometrics · 1984 · 10.2307/2530924
Exact Confidence Intervals Following a Group Sequential Test
Biometrics · 1984 · 10.2307/2530924
Current projects
No projects listed.